Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an oral tablet for oral use. It treats a range of bacterial infections, including respiratory, skin and gastrointestinal infections, in adult and pediatric patients as prescribed by a healthcare professional.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support export across multiple markets, ensuring product integrity and patient safety.

Clarithromycin is indicated for several bacterial infections affecting the respiratory tract, sinuses, skin and gastrointestinal system. - Community‑acquired pneumonia: eliminates causative bacteria and improves clinical symptoms. - Acute bacterial sinusitis: reduces infection and relieves sinus congestion. - Acute exacerbations of chronic bronchitis: shortens illness duration and improves airflow. - Skin and soft‑tissue infections: eradicates susceptible organisms and promotes healing. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance and ulcer healing.

Clarithromycin may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, sometimes watery. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate. - Rash: mild skin redness or itching.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - QT interval prolongation: risk of cardiac arrhythmia. - Clostridioides difficile‑associated diarrhea: severe colitis. - Eosinophilic pneumonia: respiratory distress with eosinophil infiltration. - Stevens‑Johnson syndrome: severe skin and mucosal reaction.

When prescribing clarithromycin, clinicians should consider several precautionary measures to minimize risks. - Assess renal and hepatic function: adjust therapy if significant impairment is present. - Review patient medication list: avoid concomitant use with drugs that prolong the QT interval. - Monitor for allergic reactions: discontinue if signs of hypersensitivity appear. - Use with caution in patients with cardiac arrhythmias: evaluate baseline ECG. - Avoid use during known macrolide resistance: consider susceptibility testing. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Clarithromycin interacts with a variety of medicines; the significance of the interaction determines the management approach.

Major Interactions (Avoid): - Cisapride: risk of serious cardiac arrhythmias; co‑administration is contraindicated. - Pimozide: may cause QT prolongation and ventricular arrhythmia; avoid combination. - Ergot alkaloids: risk of severe vasospasm; avoid. - Theophylline: increased serum levels leading to toxicity; avoid. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of rhabdomyolysis; avoid.

Moderate Interactions (Monitor Closely): - Carbamazepine: may reduce clarithromycin levels; monitor efficacy. - Warfarin: may increase INR; monitor coagulation parameters. - Oral contraceptives: may reduce effectiveness; advise additional contraception. - Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours. - Digoxin: possible increased serum concentrations; monitor levels.